Monte Rosa Therapeutics, Inc.: financial statements

GLUENASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$8.85

November 19, 2026Market cap $756M

What Ploutos Investor adds for Monte Rosa Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

Line202320242025Average a year
Revenue $0$76M$124M
Operating income -$143M-$81M-$54M
Net income -$135M-$73M-$39M
Margins
Operating margin –-107.3%-43.8%
Net margin –-96.1%-31.2%

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$39M Leases70% Pensions funded2.8% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$39M

Finance leases

$0

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Pension plans

Dec 31, 2025

Defined-benefit pensions

70%funded

Deficit $5.3M.

The obligation is the present value of the pensions employees have already earned, at December 31, 2025. A deficit is the company's to fill with contributions. The filing

ObligationPlan assets

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

2.8%

-18.2 pts

The company paid 2.8% in tax on its profit, 18.2 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Share-based compensation

-13.9 pts

Difference the filing does not itemize

-4.3 pts

Effective rate

2.8%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

$4.2M ahead of the shares0.5% of market value

Besides its $36M of debt, $4.2M of other claims rank ahead of the shares, about 0.5% of the market value.

Ahead of the shares

at Dec 31, 2025; $5.3M before tax, after tax at 21%
$4.2M

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 19, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

The full analysis

What do Monte Rosa Therapeutics's filings show?

These are Monte Rosa Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about GLUE's financials

Didn't find what you were looking for?

Ask us
How much revenue did GLUE have in 2025?

Monte Rosa Therapeutics had revenue of $124M and net income of -$39M in fiscal 2025, a net margin of -31.2%.

How much debt does GLUE have?

On December 31, 2025 Monte Rosa Therapeutics had total assets of $449M, debt of – and shareholders' equity of $233M.

How much free cash flow does GLUE have?

In fiscal 2025 Monte Rosa Therapeutics had cash from operations of -$23M and spent $4.7M on capital expenditure, leaving -$27M of free cash flow.

Where are the figures from?

From Monte Rosa Therapeutics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.